Marilyn Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marilyn Silva has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
C. Lewis
Department of Pesticide Regulation, California Environmental Protection Agency (CalEPA), Sacramento, California
1 shared publicationE. Kwok
Department of Pesticide Regulation, California Environmental Protection Agency (CalEPA), Sacramento, California
1 shared publication- Gina Solomon
Chief, Occupational, Environmental and Climate Medicine, University of California, San Francisco
1 shared publication L. Zeise
CalEPA's Office of Environmental Health Hazard Assessment (OEHHA), Sacramento, California
1 shared publicationN. Pham
CalEPA's Office of Environmental Health Hazard Assessment (OEHHA), Sacramento, California
1 shared publicationPoorni Iyer
Office of Environmental Health Hazard Assessment California Environmental Protection Agency Sacramento California
1 shared publication
Latest Publications
- 1 April 2015
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 104 (2) , 71-89
A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion
INTRODUCTION: The U.S. Environmental Protection Agency's (EPA's) Toxicity Forecaster (ToxCast) is a potential tool for chemical prioritization, hazard identification, and risk assessment. We conducted a case study to compare ToxCast data with endpoints from other in vitro and in vivo studies for two data‐rich pesticides: endosulfan and methidathion.METHODS: ToxCast assays for endocrine disruption, development (zebrafish), and neurotoxicity were qualitatively compared to traditional neurotoxicity, developmental and reproductive toxicity findings. We also used in vitro–in vivo extrapolation to convert half‐maximal activity concentrations in active ToxCast assays to rat oral equivalent doses, and quantitatively compared these to the lowest observable effect level (LOEL) from in vivo studies.RESULTS: Endosulfan was inactive for GABAAR, unlike in vivo; but active with dopamine transporter assays and was neurotoxic in zebrafish as expected. Methidathion was not active for these endpoints in vivo or in vitro. Acetylcholinesterase inhibition was ToxCast‐inactive, although both pesticides are inhibitors in vivo. ToxCast results were generally inactive for endosulfan estrogen receptor agonism and androgen receptor antagonism unlike in vivo. Calculated oral equivalent doses for estrogen receptor and androgen receptor pathways and for zebrafish assays for both compounds were generally consistent with in vivo LOELs. Endosulfan showed neurotoxicity and both pesticides showed developmental effects in the zebrafish assays, although methidathion is not developmentally toxic in vivo.CONCLUSIONS: ToxCast's predictions showed concordance on some endpoints and nonconcordance, consisting mainly of false inactives, in several critical endpoints, likely due to a lack of metabolic activation and limitations in assay design. Zebrafish assays were good predictors of developmental toxicity and neurotoxicity for endosulfan
- 1 April 2015
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 104 (2) , 71-89
A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion
INTRODUCTION: The U.S. Environmental Protection Agency's (EPA's) Toxicity Forecaster (ToxCast) is a potential tool for chemical prioritization, hazard identification, and risk assessment. We conducted a case study to compare ToxCast data with endpoints from other in vitro and in vivo studies for two data‐rich pesticides: endosulfan and methidathion.METHODS: ToxCast assays for endocrine disruption, development (zebrafish), and neurotoxicity were qualitatively compared to traditional neurotoxicity, developmental and reproductive toxicity findings. We also used in vitro–in vivo extrapolation to convert half‐maximal activity concentrations in active ToxCast assays to rat oral equivalent doses, and quantitatively compared these to the lowest observable effect level (LOEL) from in vivo studies.RESULTS: Endosulfan was inactive for GABAAR, unlike in vivo; but active with dopamine transporter assays and was neurotoxic in zebrafish as expected. Methidathion was not active for these endpoints in vivo or in vitro. Acetylcholinesterase inhibition was ToxCast‐inactive, although both pesticides are inhibitors in vivo. ToxCast results were generally inactive for endosulfan estrogen receptor agonism and androgen receptor antagonism unlike in vivo. Calculated oral equivalent doses for estrogen receptor and androgen receptor pathways and for zebrafish assays for both compounds were generally consistent with in vivo LOELs. Endosulfan showed neurotoxicity and both pesticides showed developmental effects in the zebrafish assays, although methidathion is not developmentally toxic in vivo.CONCLUSIONS: ToxCast's predictions showed concordance on some endpoints and nonconcordance, consisting mainly of false inactives, in several critical endpoints, likely due to a lack of metabolic activation and limitations in assay design. Zebrafish assays were good predictors of developmental toxicity and neurotoxicity for endosulfan
- Open Access
- 1 January 2015
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Medical Toxicology and Clinical Forensic Medicine
Comparative Toxicity of Endosulfan and Fipronil Insecticides: Utilizing In Vivo and In Vitro Data
Background: Endosulfan, an organochlorine compound, and fipronil, a phenylpyrazole, are insecticides with a common mechanism of toxicity. They interfere with Cl- influx by binding to the gamma-aminobutyric acid receptor (GABAAR) and blocking the inhibitory actions of GABAA. In vivo they cause neurotoxicity, hepatotoxicity, developmental toxicity, and can alter endocrine and immune systems. The thyroid is a target of fipronil toxicity. Human exposure occurs via food residues, skin contact and/or air dispersion. They are environmentally persistent and bioaccumulate in food chains. Method: Compare in vivo data with in vitro results from the U.S. Environmental Protection Agency (USEPA) Toxicology Forecaster (ToxCast) high-throughput screening assays and zebrafish models to assess their usefulness in predicting toxicity. Results: Fipronil’s in vivo toxicity occurred at lower doses than endosulfan for similar effects. ToxCast was a weak predictor of liver toxicity and estrogen receptor interaction. Missing is evidence of “true actives” for fipronil ToxCast assays with the thyroid receptor and for either compound with GABAAR or androgen receptors. Zebrafish models were good predictors of endosulfan and fipronil neurotoxicity in mammalian in vivo studies. Conclusion: ToxCast assays do not provide support for in vivo neurotoxicity or endocrine disruption where zebrafishs are good predictors of both parameters.
- 1 January 2015
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Medical Toxicology and Clinical Forensic Medicine
Open AccessComparative Toxicity of Endosulfan and Fipronil Insecticides: Utilizing In Vivo and In Vitro Data
Background: Endosulfan, an organochlorine compound, and fipronil, a phenylpyrazole, are insecticides with a common mechanism of toxicity. They interfere with Cl- influx by binding to the gamma-aminobutyric acid receptor (GABAAR) and blocking the inhibitory actions of GABAA. In vivo they cause neurotoxicity, hepatotoxicity, developmental toxicity, and can alter endocrine and immune systems. The thyroid is a target of fipronil toxicity. Human exposure occurs via food residues, skin contact and/or air dispersion. They are environmentally persistent and bioaccumulate in food chains. Method: Compare in vivo data with in vitro results from the U.S. Environmental Protection Agency (USEPA) Toxicology Forecaster (ToxCast) high-throughput screening assays and zebrafish models to assess their usefulness in predicting toxicity. Results: Fipronil’s in vivo toxicity occurred at lower doses than endosulfan for similar effects. ToxCast was a weak predictor of liver toxicity and estrogen receptor interaction. Missing is evidence of “true actives” for fipronil ToxCast assays with the thyroid receptor and for either compound with GABAAR or androgen receptors. Zebrafish models were good predictors of endosulfan and fipronil neurotoxicity in mammalian in vivo studies. Conclusion: ToxCast assays do not provide support for in vivo neurotoxicity or endocrine disruption where zebrafishs are good predictors of both parameters.
- 30 July 2014
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 101 (4) , 308-324
Toxicity Endpoint Selections for a Simazine Risk Assessment
BACKGROUND: California uses simazine at one of the highest levels for states in the United States (approximately 2.5 million lbs 2006–2010). Simazine causes neuroendocrine disruption and mammary cancer in test animals. A risk assessment was prioritized by the California Department of Pesticide Regulation because of the nondietary concern for simazine exposure to occupational/nonoccupational simazine users, resident nonusers, and bystanders (especially children and children exhibiting pica) at greatest risk.METHODS: No observed effect levels (NOELs) from animal studies as well as human exposure data were used to determine nondietary values for the above populations. Registrant‐submitted and open literature studies focusing on oral (major human route) effects for simazine and the major metabolites desisopropyl‐s‐atrazine and diaminochlorotriazine were reviewed as part of the hazard identification process.RESULTS: Developmental, reproduction, and chronic studies provided the lowest NOELs for the acute (5 mg/kg/day), subchronic (0.56 mg/kg/day), and chronic (0.52 mg/kg/day) exposure durations, respectively. A benchmark dose (95th percentile) was calculated for mammary tumorigenesis, assuming a threshold mechanism in rats (benchmark dose lower limit [95th percentile; BMDL05]: 2.9 mg/kg/day). Margins of exposure and uncertainty factors (100–300×, depending on exposure scenario) were used to characterize risk for designated population subgroups.CONCLUSIONS: Fetal developmental delays, endocrine disruption, and mammary tumors resulted from simazine treatment. Systemic and maternal/fetal effects determined the critical NOELs used in risk assessment. Margins of exposures for most scenarios were below acceptable levels, especially for children who may be bystanders where simazine is applied and children who exhibit pica. This risk characterization raises a concern for long‐term effects in humans
- 30 July 2014
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 101 (4) , 308-324
Toxicity Endpoint Selections for a Simazine Risk Assessment
BACKGROUND: California uses simazine at one of the highest levels for states in the United States (approximately 2.5 million lbs 2006–2010). Simazine causes neuroendocrine disruption and mammary cancer in test animals. A risk assessment was prioritized by the California Department of Pesticide Regulation because of the nondietary concern for simazine exposure to occupational/nonoccupational simazine users, resident nonusers, and bystanders (especially children and children exhibiting pica) at greatest risk.METHODS: No observed effect levels (NOELs) from animal studies as well as human exposure data were used to determine nondietary values for the above populations. Registrant‐submitted and open literature studies focusing on oral (major human route) effects for simazine and the major metabolites desisopropyl‐s‐atrazine and diaminochlorotriazine were reviewed as part of the hazard identification process.RESULTS: Developmental, reproduction, and chronic studies provided the lowest NOELs for the acute (5 mg/kg/day), subchronic (0.56 mg/kg/day), and chronic (0.52 mg/kg/day) exposure durations, respectively. A benchmark dose (95th percentile) was calculated for mammary tumorigenesis, assuming a threshold mechanism in rats (benchmark dose lower limit [95th percentile; BMDL05]: 2.9 mg/kg/day). Margins of exposure and uncertainty factors (100–300×, depending on exposure scenario) were used to characterize risk for designated population subgroups.CONCLUSIONS: Fetal developmental delays, endocrine disruption, and mammary tumors resulted from simazine treatment. Systemic and maternal/fetal effects determined the critical NOELs used in risk assessment. Margins of exposures for most scenarios were below acceptable levels, especially for children who may be bystanders where simazine is applied and children who exhibit pica. This risk characterization raises a concern for long‐term effects in humans